Evidence map›Paper›PMID 34503160›Full record

ArticleCancers2021

A Nuclear-Directed Ribonuclease Variant Targets Cancer Stem Cells and Inhibits Migration and Invasion of Breast Cancer Cells.

Jessica Castro, Giusy Tornillo, Gerardo Ceada, Beatriz Ramos-Neble, Marlon Bravo, Marc Ribó, Maria Vilanova, Matthew J Smalley, Antoni Benito

Open access · goldAbstract read
In one paragraph

Article in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 2 countries.

Jessica CastroLaboratori d'Enginyeria de Proteïnes, Departament de Biologia, Facultat de Ciències, Campus de Montilivi, Universitat de Girona, Maria Aurèlia Capmany 40, 17003 Girona, Spain.ORCID 0000-0003-4766-2311
Giusy TornilloEuropean Cancer Stem Cell Research Institute, School of Biosciences, Hadyn Ellis Building, Cardiff University, Cardiff CF24 4HQ, UK.
Gerardo CeadaLaboratori d'Enginyeria de Proteïnes, Departament de Biologia, Facultat de Ciències, Campus de Montilivi, Universitat de Girona, Maria Aurèlia Capmany 40, 17003 Girona, Spain.ORCID 0000-0002-0524-4018
Beatriz Ramos-NebleLaboratori d'Enginyeria de Proteïnes, Departament de Biologia, Facultat de Ciències, Campus de Montilivi, Universitat de Girona, Maria Aurèlia Capmany 40, 17003 Girona, Spain.ORCID 0000-0003-1479-8490
Marlon BravoLaboratori d'Enginyeria de Proteïnes, Departament de Biologia, Facultat de Ciències, Campus de Montilivi, Universitat de Girona, Maria Aurèlia Capmany 40, 17003 Girona, Spain.ORCID 0000-0002-0065-9812
Marc RibóLaboratori d'Enginyeria de Proteïnes, Departament de Biologia, Facultat de Ciències, Campus de Montilivi, Universitat de Girona, Maria Aurèlia Capmany 40, 17003 Girona, Spain.ORCID 0000-0001-6944-6383
Maria VilanovaLaboratori d'Enginyeria de Proteïnes, Departament de Biologia, Facultat de Ciències, Campus de Montilivi, Universitat de Girona, Maria Aurèlia Capmany 40, 17003 Girona, Spain.ORCID 0000-0003-0523-815X
Matthew J SmalleyEuropean Cancer Stem Cell Research Institute, School of Biosciences, Hadyn Ellis Building, Cardiff University, Cardiff CF24 4HQ, UK.
Antoni BenitoLaboratori d'Enginyeria de Proteïnes, Departament de Biologia, Facultat de Ciències, Campus de Montilivi, Universitat de Girona, Maria Aurèlia Capmany 40, 17003 Girona, Spain.ORCID 0000-0002-9776-1003
Universitat de Girona · ESCardiff University · GB

Funding

Breast Cancer Now 2018NovPR1211Breast Cancer Research Aid Does not applyMinisterio de Economía y Competitividad BIO2013-43517Universitat de Girona MPCU2016/18
6 · The paper itself

Abstract

Despite the significant advances in cancer research made in recent years, this disease remains one of the leading causes of death worldwide. In part, this is due to the fact that after therapy, a subpopulation of self-renewing tumor cells can survive and promote cancer relapse, resistance to therapies and metastasis. Targeting these cancer stem cells (CSCs) is therefore essential to improve the clinical outcome of cancer patients. In this sense, multi-targeted drugs may be promising agents targeting CSC-associated multifocal effects. We have previously constructed different human pancreatic ribonuclease (RNase) variants that are cytotoxic for tumor cells due to a non-classical nuclear localization signal introduced in their sequence. These cytotoxic RNases affect the expression of multiple genes involved in deregulated metabolic and signaling pathways in cancer cells and are highly cytotoxic for multidrug-resistant tumor cell lines. Here, we show that these cytotoxic nuclear-directed RNases are highly selective for tumor cell lines grown in 3D, inhibit CSCs' development and diminish the self-renewal capacity of the CSCs population. Moreover, these human RNase variants reduce the migration and invasiveness of highly invasive breast cancer cells and downregulate N-cadherin expression.

Indexed as

anticancer drugcancer stem cellsdrug selectivityinvasionribonuclease

Identifiers

PMID34503160
PMCPMC8430808
OpenAlexW3196689147

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.